Company intelligence / Profile preview
Gritgen Therapeutics Co., Ltd.
Suzhou, Chinagritgen.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
GS1191, their lead product for Hemophilia A, has demonstrated excellent safety and sustained bleed control efficacy in clinical trials. Early data showed it can consistently increase FVIII activity in the blood, resulting in fewer bleeding episodes. Patients given the higher dose reached normal FVIII activity levels and had no bleeding episodes after dosing. Most side effects were mild with no serious side effects reported.
- Therapeutic areas
- ImmunologyMetabolic DisordersRare DiseasesHematology
- Modalities
- Gene therapyAAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Gritgen Therapeutics Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gritgen Therapeutics Co., Ltd..